|
|
Home
Peptagen, Inc. is a small biotechnology company that is developing cytotoxic T-lymphocyte (CTL) vaccine products for the prevention and treatment of pathogenic diseases and cancer via nasal nanoparticle-enabled delivery. The technology, called CIMvac (cytotoxic T lymphocyte immune modulator vaccine), uses modified endogenous peptides to enhance or direct a cellular immune response.
Peptagen, Inc is committed to the research and development of effective innovative vaccine compositions for the treatment and prevention of pathogenic disease and cancer. Our team is fully-dedicated to improving the quality and length of life for many patients, increasing the understanding of the CTL vaccine capability, and reducing the worldwide incidences of cancer, HIV/AIDS and other pathogenic diseases by producing effective therapeutic and preventative vaccine products.
©2010 Peptagen, Inc. All Rights Reserved
| | | | | |